BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced manageme

Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeli

Explore the exciting world of Vertex Pharmaceuticals (VRTX +1.44%) with our contributing expert anal

Vertex Pharmaceuticals' business could be in trouble if it faces competition in its core market. How

Vertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area. The company

I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis

KING OF PRUSSIA, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the

Vertex Pharmaceuticals could face competition in its most important market by far. The company is pr

Vertex (VERX) could produce exceptional returns because of its solid growth attributes.

Its sales rose at a double-digit rate; net profit growth was more modest. There's another developmen

Gainers Corvex (NASDAQ:MOVE) stock moved upwards by 44.6% to $15.56 during Tuesday's regular se

DA Davidson analyst Lucky Schreiner maintains Vertex (NASDAQ:VERX) with a Neutral and lowers the

Vertex Inc (NASDAQ:VERX) reported upbeat earnings for the second quarter on Monday.

Vertex Inc (NASDAQ:VERX) reported strong Q2 earnings, exceeding analyst estimates. Sales for Q3 also

Stephens & Co. analyst Brett Huff maintains Vertex (NASDAQ:VERX) with a Overweight and lowers

KING OF PRUSSIA, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ: VERX), the Decision-to-

Baird analyst Rob Oliver maintains Vertex (NASDAQ:VERX) with a Outperform and lowers the price ta

Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech

Vertex, Inc. (VERX) Q2 2026 Earnings Call Transcript

Vertex NASDAQ: VERX reported second-quarter revenue at the high end of its guidance range and raised

Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over yea

The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter en

Vertex (VERX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estima

Vertex (NASDAQ:VERX) narrows FY2026 sales outlook from $823.500 million-$831.500 million to $825.000

Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its s

Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on rob

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.20 per share which beat the analyst consensus

Morgan Stanley analyst Chris Quintero downgrades Vertex (NASDAQ:VERX) from Overweight to Equal-We

TD Cowen analyst Jared Levine initiates coverage on Vertex (NASDAQ:VERX) with a Buy rating and an

Citigroup analyst Steven Enders maintains Vertex (NASDAQ:VERX) with a Neutral and raises the pric

Piper Sandler analyst Billy Fitzsimmons maintains Vertex (NASDAQ:VERX) with a Neutral and raises

Vertex (NASDAQ:VERX) affirms FY2026 sales outlook from $823.500 million-$831.500 million to $823.500

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.17 per share which met the analyst consensus

BMO Capital analyst Daniel Jester maintains Vertex (NASDAQ:VERX) with a Market Perform and lowers

Goldman Sachs analyst Adam Hotchkiss maintains Vertex (NASDAQ:VERX) with a Buy and lowers the pri

Citizens analyst Patrick Walravens maintains Vertex (NASDAQ:VERX) with a Market Outperform and lo

Piper Sandler analyst Billy Fitzsimmons maintains Vertex (NASDAQ:VERX) with a Neutral and lowers

Needham analyst Joshua Reilly maintains Vertex (NASDAQ:VERX) with a Buy and lowers the price targ

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.17 per share which beat the analyst consensus

Piper Sandler analyst Hannah Rudoff downgrades Vertex (NASDAQ:VERX) from Overweight to Neutral an

Goldman Sachs sees a familiar pattern returning in 2026: prior-year laggards often beat the S&P

Goldman Sachs analyst Adam Hotchkiss maintains Vertex (NASDAQ:VERX) with a Buy and lowers the pri

Piper Sandler analyst Hannah Rudoff maintains Vertex (NASDAQ:VERX) with a Overweight and lowers t

BMO Capital analyst Daniel Jester maintains Vertex (NASDAQ:VERX) with a Market Perform and lowers

Citizens analyst Patrick Walravens maintains Vertex (NASDAQ:VERX) with a Market Outperform and lo

Stifel analyst Brad Reback maintains Vertex (NASDAQ:VERX) with a Hold and lowers the price target